{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:15:04Z","timestamp":1737522904968,"version":"3.33.0"},"reference-count":18,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSO"],"published-print":{"date-parts":[[2024,8,25]]},"abstract":"<jats:p>Objective: The aim of this study is to compare the results of preoperative biometric data measured with optical biometers of different generations in patients with cataract. Lenstar optical biometry is based on the principle of optical low-coherence reflectometry (OLCR), and Anterion on swept-source optical coherence tomography (SS-OCT).\n\nMaterial and methods: A total of 200 eyes (103 patients) were included in a prospective study at the Faculty Hospital in Tren\u010d\u00edn the period from June 2023 to January 2024. We compared the results of 6 parameters: axial length (AL), mean keratometry (K), lens thickness (LT), white-to-white diameter (WTW), astigmatism (AST), and intraocular lens (IOL) power. The results were statistically analyzed.\n\nResults: The values of AL, AST, and IOL parameters between the Lenstar and Anterion biometers were consistent, with no statistically significant difference (p = 0.593; p = 0.089; p = 0.069). The values of K, LT, and WTW showed statistically significant differences (p &lt; 0.001). A Bland-Altman plot analysis confirmed good concordance between the parameters within a 95% limit of agreement.\n\nConclusion: Biometric data measurement using SS-OCT Anterion is reliable, quick, and the results are comparable to those obtained with Lenstar. The AL, AST, and estimated IOL values were consistent between the biometers. Despite differences in the measurements of LT, WTW, and K parameters, the final IOL value was the same. In addition to biometric data, Anterion provides comprehensive tomographic examination of the cornea and OCT scanning of the anterior segment.<\/jats:p>","DOI":"10.31348\/2024\/35","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:01:51Z","timestamp":1737460911000},"page":"318-322","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Optical Biometry Data Measured with Lenstar and Anterion Devices"],"prefix":"10.31348","volume":"80","author":[{"given":"Zuzana","family":"Anwarzai \u0160ulav\u00edkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Palkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2024,8,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Daruich A, Bremond-Gignac D, Behar-Cohen F, Kermorvant E. R\u00e9tinopathie du pr\u00e9matur\u00e9: de la pr\u00e9vention au traitement [Retinopathy of prematurity: from prevention to treatment]. Med Sci (Paris). 2020 Oct;36(10):900-907. French. doi: 10.1051\/medsci\/2020163","DOI":"10.1051\/medsci\/2020163"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"de las Rivas Ram\u00edrez N, Luque Aranda G, Rius D\u00edaz F, et al. Risk factors associated with Retinopathy of Prematurity development and progression. Sci Rep. 2020;12:21977.","DOI":"10.1038\/s41598-022-26229-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current tre-atment strategies. Clin Exp Pediatr. 2022 Mar;65(3):115-126. doi: 10.3345\/cep.2021.00773","DOI":"10.3345\/cep.2021.00773"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016\/j.ophtha.2021.05.031","DOI":"10.1016\/j.ophtha.2021.10.021"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R; Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmo-logists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Gui-delines. Early Hum Dev. 2023 Mar;177-178:105715. doi: 10.1016\/j.earlhumdev.2023.105715","DOI":"10.1016\/j.earlhumdev.2023.105715"},{"key":"ref5","unstructured":"Kanski\u2019s Clinical Ophtalmology 2020; p.538."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248; discussion 248-520.","DOI":"10.1093\/med\/9780190050726.003.0027"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zobanov\u00e1 A, Brychc\u00ednov\u00e1 P, Autrata R, \u0160enkov\u00e1 K. Screening, Treatment and Long-term Observa-tion of Retinopathy of Prematurely Born Children in the Czech Republic. Cesk Slov Oftalmol. 2018;74(6):253-264.","DOI":"10.31348\/2018\/6\/7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103\/sjopt.sjopt_18_22","DOI":"10.4103\/sjopt.sjopt_18_22"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wood EH, Chang EY, Beck K, et al. 80 Years of vision: preventing blindness from retinopathy of prematurity. J Perinatol. 2021 Jun;41(6):1216-1224. doi: 10.1038\/s41372-021-01015-8","DOI":"10.1038\/s41372-021-01015-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Yucel OE, Eraydin B, Niyaz L, Terzi O. Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants. BMC Ophthal-mol. 2022 Sep 13;22(1):367. doi: 10.1186\/s12886-022-02591-9","DOI":"10.1186\/s12886-022-02591-9"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dogra MR, Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Tre-atment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Coun-tries. Pediatric Health Med Ther. 2023 Feb 15;14:59-69. doi: 10.2147\/PHMT.S391591","DOI":"10.2147\/phmt.s391591"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Enr\u00edquez AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097\/APO.0000000000000302","DOI":"10.1097\/apo.0000000000000302"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of Prematurity: A Global Perspective and Recent Developments. Pediatrics. 2022 Sep 1;150(3):e2021053924. doi: 10.1542\/peds.2021-053924. PMID: 35948728","DOI":"10.1542\/peds.2021-053924"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. E J Ophthalmol. 2012 Sep-Oct;22(5):687-694. doi: 10.5301\/ejo.5000166","DOI":"10.5301\/ejo.5000166"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fierson WM; American academy of pediatrics section on ophthalmology; american academy of ophthalmology; american association for pediatric ophthalmology and strabismus; american asso-ciation of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018 Dec;142(6): e20183061. doi: 10.1542\/peds.2018-3061. Erratum in: Pe-diatrics. 2019 Mar;143(3)","DOI":"10.1542\/peds.2018-3810"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020 Oct; 218:208-213. doi: 10.1016\/j.ajo.2020.05.025, Erratum in: Am J Ophthalmol. 2021 Nov; 231:213","DOI":"10.1016\/j.ajo.2020.12.018"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhang Z, Wang Y, Di Y. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Front Pharmacol. 2022 Aug 22; 13:897869. doi: 10.3389\/fphar.2022.897869","DOI":"10.3389\/fphar.2022.897869"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:01:56Z","timestamp":1737460916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,25]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2024,10,14]]}},"URL":"https:\/\/doi.org\/10.31348\/2024\/35","relation":{},"ISSN":["1805-4447","1211-9059"],"issn-type":[{"value":"1805-4447","type":"electronic"},{"value":"1211-9059","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,25]]}}}